Employees compassionately help local communities with country-wide food drive
Coming together to bring food to people in need
Search
Boehringer Ingelheim’s Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation
Boehringer Ingelheim’s Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation
Topline results from Boehringer's Phase III IPF Study
Press release announcing topline results of Boehringer Ingelheim's Phase III FIBRONEER-IPF study in indiopathic pulmonary fibrosis
Cooking Up Change: Boehringer Cares Foundation and World Central Kitchen’s Recipe for Fighting Hunger
Our Boehringer Cares team has partnered with World Central Kitchen who aim to address the critical issue of global food insecurity.
Boehringer included on LinkedIn’s “Top Companies 2024” list
Investing in our people is at the core of what we do
2024 HBA Luminary from Boehringer Ingelheim recognized for putting patients first
Nicole Forman receives notable award for her commitment to health equity.
AI-Driven Model Validated to Predict Risk of CKD Progression
Boehringer Ingelheim and Carelon Research conducted the first large-scale U.S. validation of a new AI-driven tool to predict the risk of CKD progression.
New effort to help improve C-R-M health outcomes
Boehringer Ingelheim sponsors American Heart Association's Cardiovascular Kidney Metabolic Health Intiative (CKMH)
Life forward - Boehringer Ingelheim unveils its evolved company brand
Life forward - Boehringer Ingelheim unveils its evolved company brand
Positive results reported in HER2 mutated lung cancer
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
Occupational Health and Safety
Occupational Health and Safety
BI Cares: Supporting Ukraine
Our family-owned company condemns the ongoing military aggression against Ukraine, and have maintained our support for those in need by providing financial and in-kind donations through our Boehringer Ingelheim Cares Foundation.
BI to Donate 75k Rabies Vaccine Doses | Boehringer Ingelheim US
Boehringer Ingelheim to donate 75,000 doses of IMRAB® vaccine to the Global Alliance for Rabies Control through shots for Good Initiative.
Benefits & Rewards
We invest in our people so they will stay and grow with us. We offer benefits such as rewards and development opportunities to help retain employees.
Our Purpose
Why we exist
Vetmedica Inc to Sell Vaccine Portfolio | Boehringer Ingelheim US
Read more on Boehringer Ingelheim Vetmedica Inc. entering into an agreement to sell feline, canine and rabies vaccines to Elanco Animal Health in the USA.
Boehringer Ingelheim Applauds the Governor's Prevention Partnership for Protecting Connecticut Youth from Drugs and Alcohol for 35 Years
Recently, our colleagues joined Governor Ned Lamont, and his Connecticut's Governor's Prevention Partnership organization to celebrate its 35th anniversary and reaffirm our collective commitment to keeping Connecticut youth safe and substance-free.
Supply Chain Scholarship for Cowtribe
A supply chain course we sponsored boosted the career of Latifa Saaka
Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis
Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis
U.S. FDA grants Breakthrough Therapy designation for MASH
Boehringer Ingelheim receives U.S. FDA Breakthrough Therapy designation for people living with MASH and liver fibrosis
When Passion Starts as a Family Value and Continues as a Work Value
Discover who inspires members of our LatinX Business Resource Group.
Flying animals to safety with Greater Good Charities
Watch as Julie Ryan-Johnson volunteers to take care of animals being brought to new homes following the Maui wildfires.
Health disparities in Black and African Americans
Addressing social determinants of health in cardio-kidney-metabolic care
New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status
New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
Medicines reach record number of people, net sales rise